Richard Pops, Alkermes CEO (Patrick T. Fallon/Bloomberg via Getty Images)
Alkermes is handed a CRL for ‘3831, marking another setback on the R&D front
Alkermes $ALKS is going to have to wait some more before launching its anti-psychotic combo drug ALKS-3831. The FDA has handed the biotech a CRL …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
